MCID: LNG020
MIFTS: 51

Lung Oat Cell Carcinoma

Categories: Cancer diseases, Respiratory diseases

Aliases & Classifications for Lung Oat Cell Carcinoma

MalaCards integrated aliases for Lung Oat Cell Carcinoma:

Name: Lung Oat Cell Carcinoma 12 15
Oat Cell Carcinoma of Lung 6
Carcinoma, Small Cell 44
Oat Cell Carcinoma 12
Carcinoma Oat Cell 54

Classifications:



External Ids:

Disease Ontology 12 DOID:5411
MeSH 44 D018288
NCIt 50 C3915
SNOMED-CT 67 11010461000119101
UMLS 70 C0262584

Summaries for Lung Oat Cell Carcinoma

MalaCards based summary : Lung Oat Cell Carcinoma, also known as oat cell carcinoma of lung, is related to gallbladder small cell carcinoma and carcinoid syndrome. An important gene associated with Lung Oat Cell Carcinoma is RB1 (RB Transcriptional Corepressor 1), and among its related pathways/superpathways are TNFR1 Pathway and PI3K-Akt signaling pathway. The drugs BCG vaccine and Atezolizumab have been mentioned in the context of this disorder. Affiliated tissues include lung, prostate and cervix, and related phenotypes are growth/size/body region and behavior/neurological

Related Diseases for Lung Oat Cell Carcinoma

Diseases related to Lung Oat Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 381)
# Related Disease Score Top Affiliating Genes
1 gallbladder small cell carcinoma 32.0 ENO2 CHGA
2 carcinoid syndrome 30.7 ENO2 CHGA
3 small cell carcinoma 30.5 TP53 PTEN ENO2 CHGA
4 inappropriate adh syndrome 30.1 POMC AVP
5 gallbladder cancer 29.9 TP53 PIK3CA AKT1
6 in situ carcinoma 29.9 TP53 PTEN PIK3CA AKT1
7 neuroendocrine carcinoma 29.9 PTEN ENO2 CHGA
8 cholangiocarcinoma 29.8 TP53 PIK3CA AKT1
9 papilloma 29.8 TP53 RB1 PTEN AKT1
10 acquired immunodeficiency syndrome 29.7 TP53 POMC B2M
11 ductal carcinoma in situ 29.7 TP53 PTEN PIK3CA AKT1
12 myeloma, multiple 29.6 TP53 PTEN PIK3CA B2M AKT1
13 malignant astrocytoma 29.6 TP53 PTEN CHGA AKT1
14 squamous cell carcinoma 29.6 TP53 RB1 PTEN PIK3CA AKT1
15 merkel cell carcinoma 29.5 TP53 RB1 ENO2 CHGA
16 bladder urothelial carcinoma 29.4 TP53 PTEN PIK3CA AKT1
17 adenocarcinoma 29.4 TP53 RB1 PTEN PIK3CA AKT1
18 leukemia, chronic lymphocytic 29.4 TP53 PTEN B2M AKT1
19 lung cancer susceptibility 3 29.3 TP53 RB1 PIK3CA B2M AKT1
20 small cell cancer of the lung 29.3 TP53 RB1 PTEN POMC PIK3CA ENO2
21 suppression of tumorigenicity 12 29.3 TP53 PTEN PIK3CA CHGA AKT1
22 melanoma 29.2 TP53 RB1 PTEN PIK3CA B2M AKT1
23 esophageal cancer 29.1 TP53 RB1 PTEN PIK3CA AKT1
24 bladder cancer 29.1 TP53 RB1 PTEN PIK3CA AKT1
25 adenoma 29.0 TP53 POMC PIK3CA CHGA AKT1
26 medulloblastoma 28.9 TP53 RB1 PTEN PIK3CA ENO2 AKT1
27 neuroblastoma 28.7 TP53 PTEN PIK3CA ENO2 CHGA AKT1
28 esophagus small cell carcinoma 11.4
29 prostate small cell carcinoma 11.2
30 dysphagia 10.3
31 vulvar adenocarcinoma 10.3 TP53 RB1
32 conjunctival squamous cell carcinoma 10.3 TP53 RB1
33 suppressor of tumorigenicity 3 10.3 TP53 RB1
34 large cell carcinoma 10.3
35 penile benign neoplasm 10.2 TP53 PIK3CA
36 parameningeal embryonal rhabdomyosarcoma 10.2 TP53 PIK3CA
37 breast juvenile papillomatosis 10.2 PIK3CA AKT1
38 familial retinoblastoma 10.2 TP53 RB1
39 ovarian carcinosarcoma 10.2 TP53 PIK3CA
40 chromosome 13q14 deletion syndrome 10.2 TP53 RB1
41 meningioma, radiation-induced 10.2 PIK3CA AKT1
42 thyroid hurthle cell adenoma 10.2 PTEN PIK3CA
43 ovarian clear cell adenofibroma 10.2 PTEN PIK3CA
44 malignant spiradenoma 10.2 TP53 PIK3CA
45 macroglossia 10.2 PTEN B2M
46 breast papillomatosis 10.2 PIK3CA AKT1
47 vulva squamous cell carcinoma 10.2 TP53 PIK3CA
48 adult teratoma 10.2 TP53 CHGA
49 gemistocytic astrocytoma 10.2 TP53 PTEN
50 breast hemangioma 10.2 TP53 AVP

Graphical network of the top 20 diseases related to Lung Oat Cell Carcinoma:



Diseases related to Lung Oat Cell Carcinoma

Symptoms & Phenotypes for Lung Oat Cell Carcinoma

MGI Mouse Phenotypes related to Lung Oat Cell Carcinoma:

46 (show all 19)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.19 AKT1 B2M CHGA ENO2 PIK3CA POMC
2 behavior/neurological MP:0005386 10.18 AKT1 AVP ENO2 PIK3CA POMC PTEN
3 homeostasis/metabolism MP:0005376 10.18 AKT1 AVP B2M CHGA PIK3CA POMC
4 cardiovascular system MP:0005385 10.17 AKT1 B2M CHGA PIK3CA POMC PTEN
5 cellular MP:0005384 10.16 AKT1 B2M ENO2 PIK3CA POMC PTEN
6 endocrine/exocrine gland MP:0005379 10.15 AKT1 B2M CHGA PIK3CA POMC PTEN
7 immune system MP:0005387 10.11 AKT1 AVP B2M PIK3CA POMC PTEN
8 mortality/aging MP:0010768 10.11 AKT1 AVP B2M CHGA PIK3CA POMC
9 nervous system MP:0003631 10.07 AKT1 AVP B2M CHGA ENO2 PIK3CA
10 adipose tissue MP:0005375 10.06 AKT1 PIK3CA POMC PTEN RB1 TP53
11 integument MP:0010771 10.04 AKT1 B2M PIK3CA POMC PTEN RB1
12 liver/biliary system MP:0005370 9.95 AKT1 B2M POMC PTEN RB1 TP53
13 neoplasm MP:0002006 9.95 AKT1 B2M PIK3CA POMC PTEN RB1
14 muscle MP:0005369 9.91 AKT1 CHGA PIK3CA PTEN RB1 TP53
15 no phenotypic analysis MP:0003012 9.8 AVP CHGA PIK3CA POMC RB1 TP53
16 renal/urinary system MP:0005367 9.63 AVP CHGA POMC PTEN RB1 TP53
17 pigmentation MP:0001186 9.56 POMC PTEN RB1 TP53
18 reproductive system MP:0005389 9.5 AKT1 B2M CHGA PIK3CA PTEN RB1
19 respiratory system MP:0005388 9.1 AKT1 AVP ENO2 PTEN RB1 TP53

Drugs & Therapeutics for Lung Oat Cell Carcinoma

Drugs for Lung Oat Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 147)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
BCG vaccine Approved, Investigational Phase 3
2
Atezolizumab Approved, Investigational Phase 2, Phase 3 1380723-44-3
3
Dopamine Approved Phase 3 62-31-7, 51-61-6 681
4
Memantine Approved, Investigational Phase 3 19982-08-2 4054
5
Belotecan Investigational Phase 3 256411-32-2
6
Camptothecin Experimental Phase 3 7689-03-4
7 Vaccines Phase 3
8 Epoetin alfa Phase 3 113427-24-0
9 Hematinics Phase 3
10 Immunoglobulins Phase 2, Phase 3
11 Antibodies Phase 2, Phase 3
12 Antibodies, Monoclonal Phase 2, Phase 3
13 Neurotransmitter Agents Phase 3
14 Dopamine Agents Phase 3
15 Excitatory Amino Acid Antagonists Phase 3
16 Antiparkinson Agents Phase 3
17
Irinotecan Approved, Investigational Phase 2 100286-90-6, 97682-44-5 60838
18
Bevacizumab Approved, Investigational Phase 2 216974-75-3
19
Arsenic trioxide Approved, Investigational Phase 2 1327-53-3 518740
20
Sargramostim Approved, Investigational Phase 2 123774-72-1, 83869-56-1
21
Lenograstim Approved, Investigational Phase 2 135968-09-1
22
Somatostatin Approved, Investigational Phase 1, Phase 2 38916-34-6, 51110-01-1 53481605
23
Temozolomide Approved, Investigational Phase 1, Phase 2 85622-93-1 5394
24
Pembrolizumab Approved Phase 1, Phase 2 1374853-91-4
25
Niraparib Approved, Investigational Phase 2 1038915-60-4 24958200
26
Durvalumab Approved, Investigational Phase 1, Phase 2 1428935-60-7
27
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
28
Methyltestosterone Approved Phase 2 58-18-4 6010
29
Testosterone Approved, Investigational Phase 2 58-22-0 6013
30
Testosterone undecanoate Approved, Investigational Phase 2 5949-44-0
31
Testosterone enanthate Approved Phase 2 315-37-7 9416
32
Talazoparib Approved, Investigational Phase 2 1207456-01-6 135565082
33
Rucaparib Approved, Investigational Phase 1, Phase 2 283173-50-2 9931954
34
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
35
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
36
Vinorelbine Approved, Investigational Phase 2 71486-22-1 60780 44424639
37
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
38
Lapatinib Approved, Investigational Phase 2 231277-92-2, 388082-78-8 208908 9941095
39
Ipilimumab Approved Phase 2 477202-00-9
40
nivolumab Approved Phase 2 946414-94-4
41
Lamivudine Approved, Investigational Phase 2 134678-17-4 60825
42
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
43
Levoleucovorin Approved, Investigational Phase 2 68538-85-2 149436
44
Pemetrexed Approved, Investigational Phase 2 150399-23-8, 137281-23-3 60843 446556
45 Bemiparin Approved, Investigational Phase 2 91449-79-5
46
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
47
Gemcitabine Approved Phase 2 95058-81-4 60750
48
Etoposide Approved Phase 2 33419-42-0 36462
49
Pomalidomide Approved Phase 1, Phase 2 19171-19-8
50
Zoledronic Acid Approved Phase 2 118072-93-8 68740

Interventional clinical trials:

(show top 50) (show all 118)
# Name Status NCT ID Phase Drugs
1 A Randomized Prospective Multicenter Trial of Belotecan/Cisplatin Versus Etoposide/Cisplatin in Patients With Previously Untreated, Extensive-stage Small-cell Lung Cancer Unknown status NCT00826644 Phase 3 Belotecan/Cisplatin;Etoposide/Cisplatin
2 Phase III Randomized Study of Hypofractionated vs Conventionally Fractionated Concurrent Chemo-radiotherapy for Limited Disease Small Cell Lung Cancer Unknown status NCT02688036 Phase 3
3 The SILVA Study: Survival in an International Phase III Prospective Randomized LD Small Cell Lung Cancer Vaccination Study With Adjuvant BEC2 and BCG Completed NCT00037713 Phase 3
4 A Placebo-Controlled Study on the Effect of Epoetin Alfa in Patients With Malignancy Receiving Chemotherapy Completed NCT00270166 Phase 3 epoetin alfa
5 Randomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial Recruiting NCT04402788 Phase 2, Phase 3 Atezolizumab
6 Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase II/III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab Recruiting NCT03811002 Phase 2, Phase 3 Atezolizumab;Carboplatin;Cisplatin;Etoposide
7 MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK) Recruiting NCT04155034 Phase 3
8 A Phase 3, Controlled, Open-label, Randomized Study of RRx-001 Administered Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond Small Cell Lung Cancer Active, not recruiting NCT03699956 Phase 3 Cisplatin/carboplatin plus etoposide
9 Phase III Trial of Stereotactic Radiosurgery (SRS) Versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or Fewer Brain Metastases From Small Cell Lung Cancer Not yet recruiting NCT04804644 Phase 3 Memantine Hydrochloride
10 Phase 2 Study of Temozolomide as Maintenance Therapy After Initial Induction Chemotherapy in Small Cell Lung Cancer Unknown status NCT01900951 Phase 2 Temozolomide
11 Open Label Study of Single Dose Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy Unknown status NCT00100256 Phase 1, Phase 2 Rhenium (Re 188 P2045, BAY86-5284)
12 Phase Ⅱ Study of Relationship Between UGT1A1 Gene Polymorphism and Toxicity and Efficacy of Irinotecan in Small Cell Lung Cancer Unknown status NCT01635400 Phase 2 Irinotecan
13 A Phase II Trial of Irinotecan, Carboplatin, Bevacizumab in the Treatment of Patients With Extensive Stage Small Cell Lung Cancer Completed NCT00294931 Phase 2 irinotecan;carboplatin;bevacizumab
14 Phase II Trial of ALIMTA in Relapsed Small Cell Lung Cancer Completed NCT00191750 Phase 2 Pemetrexed
15 An Open-label Phase II Trial to Investigate the Efficacy, Safety, and Pharmacokinetics of a Single Dose of 200 mg i.v. BI 2536 Administered Every 21 Days in Patients With Sensitive Relapse Small Cell Lung Cancer Completed NCT00412880 Phase 2 BI 2536
16 Phase 2 Open-Label, Multicenter Clinical Study of the Safety and Efficacy of Intravenous Administration of SNS-595 in Patients With Advanced Small Cell Lung Cancer (SCLC) Completed NCT00298896 Phase 2 SNS-595
17 A Phase II Trial of Topotecan and Carboplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer Completed NCT00305942 Phase 2 Topotecan;carboplatin
18 Phase I/II Study to Investigate the Safety, Tolerability, Efficacy and Pharmacokinetics of ZK 219477 in Combination With Cisplatin as First-line Therapy in Chemotherapy-naïve Patients With Extensive-disease (ED) Stage Small-cell Lung Cancer (SCLC) Completed NCT00359359 Phase 1, Phase 2 Sagopilone (BAY86-5302, ZK 219477);Cisplatin
19 Phase II Study of Irinotecan, Carboplatin, Bevacizumab, and Radiation Therapy in the Treatment of Patients With Limited Stage Small Cell Lung Cancer Completed NCT00308529 Phase 2 irinotecan;carboplatin;bevacizumab
20 A Phase II Trial of VInflunine in the Treatment of Patients With Relapsed Extensive Small Cell Lung Cancer Completed NCT00284154 Phase 2 Vinflunine
21 A Phase I/II Study of Radiation Dose Intensity Concurrent With Chemotherapy For Limited Stage Small Cell Lung Cancer Completed NCT00126828 Phase 1, Phase 2
22 Combination Chemotherapy With or Without Maintenance Sunitinib Malate (NSC 736511) for Untreated Extensive Stage Small Cell Lung Cancer: A Phase IB/Randomized Phase II Study Completed NCT00453154 Phase 1, Phase 2 Carboplatin;Cisplatin;Etoposide;Sunitinib Malate
23 A Single Arm, Two-Stage Phase II Study of Arsenic Trioxide in Previously Treated Small Cell Lung Cancer Completed NCT01470248 Phase 2 Arsenic Trioxide
24 Utility of Preoperative FDG-PET/CT Scanning Prior to Primary Chemoradiation Therapy to Detect Retroperitoneal Lymph Node Metastasis in Patients With Locoregionally Advanced Carcinoma of the Cervix (IB2, IIA ≥ 4 CM, IIB-IVA) or Endometrium (Grade 3 Endometrioid Endometrial Carcinoma; Serous Papillary Carcinoma, Clear Cell Carcinoma, or Carcinosarcoma (Any Grade); and Grade 1 OR 2 Endometrioid Endometrial Carcinoma With Cervical Stromal Involvement Overt in Clinical Examination or Confirmed by Endocervical Curettage Completed NCT00416455 Phase 1, Phase 2 ferumoxtran-10
25 A Phase II Evaluation of ABI-007 in the Treatment of Persistent or Recurrent Squamous or Nonsquamous Cell Carcinoma of the Cervix Completed NCT00309959 Phase 2 Paclitaxel Albumin-Stabilized Nanoparticle Formulation
26 A Phase II Evaluation of ABT-888 (NCI Supplied Agent: ABT-888, NSC #737664), Topotecan (NSC # 609699) and Filgrastim or Pegfilgrastim in the Treatment of Persistent or Recurrent Squamous or Non-squamous Cell Carcinoma of the Cervix Completed NCT01266447 Phase 2 Topotecan Hydrochloride;Veliparib
27 An Open Label Phase I/II Study of Cabazitaxel With or Without Carboplatin in Patients With Metastatic Castration-Resistant Prostate Cancer Completed NCT01505868 Phase 1, Phase 2 Cabazitaxel;Carboplatin
28 A Phase II Study Of Higher Dose Weekly Topotecan In The Treatment Of Patients With Extensive Stage Small-Cell Lung Cancer Completed NCT00294190 Phase 2 Topotecan
29 Prospective Evaluation of Pelvic Exenteration in Patients With Recurrent Cervical Cancer Completed NCT00217633 Phase 2
30 Phase II Study to Determine the Efficacy of OSI-211 (Liposomal Lurtotecan) Given on Days 1, 2 & 3 Every 3 Weeks in Patients With Recurrent Small Cell Lung Cancer Completed NCT00046787 Phase 2 OSI-211 (Liposomal Lurtotecan)
31 A Phase 1/2a, Open-label Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of PEN-221 in Patients With Somatostatin Receptor 2 Expressing Advanced Cancers, Including Gastroenteropancreatic or Lung or Thymus or Other Neuroendocrine Tumors or Small Cell Lung Cancer or Large Cell Neuroendocrine Carcinoma of the Lung Completed NCT02936323 Phase 1, Phase 2 PEN-221
32 A Clinical Trial of Increased Chest Radiotherapy Dose for Limited Stage Small Cell Lung Cancer Completed NCT00907569 Phase 2
33 Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination With Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer Completed NCT01642251 Phase 1, Phase 2 Cisplatin;Etoposide;Veliparib;Placebo
34 PHASE 1-2 STUDY EVALUATING HIGH DOSE ADXS11-001 (1 x 10^10 CFU) TREATMENT IN WOMEN WITH HPV+ CARCINOMA OF THE CERVIX Completed NCT02164461 Phase 1, Phase 2
35 Safety Run-In and Phase II Trial of M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers Recruiting NCT03554473 Phase 1, Phase 2 M7824;Topotecan;Temozolomide
36 Phase II, Single-Arm Study of Low-Dose Radiotherapy (LDRT) Concurrent Cisplatin/Carboplatin Plus Etoposide With Atezolizumab for Patients With Extensive-Stage Small Cell Lung Cancer Recruiting NCT04622228 Phase 2 Atezolizumab;Cisplatin;Carboplatin;Etoposide
37 Niraparib (PARP Inhibitor) Plus Dostarlimab (Anti-PD1) for Small Cell Lung Cancer (SCLC) and Other High-Grade Neuroendocrine Carcinomas (NEC) Recruiting NCT04701307 Phase 2 Niraparib
38 Randomized Phase II Trial of Topotecan Plus M6620 (VX-970) vs. Topotecan Alone in Patients With Relapsed Small-Cell Lung Cancer Recruiting NCT03896503 Phase 2 Berzosertib;Topotecan Hydrochloride
39 Phase 1b/2 Study of BXCL701, a Small Molecule Inhibitor of Dipeptidyl Peptidases, Administered in Combination With the Anti-Programmed Cell Death 1 Monoclonal Antibody Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype Recruiting NCT03910660 Phase 1, Phase 2 Talabostat Mesylate plus Pembrolizumab
40 An Open-Label Phase 1b Dose-Finding Trial Evaluating the Safety of Niraparib and Temozolomide and Atezolizumab in Participants With Advanced Solid Tumors and Expansion to a Phase 2 Trial Comparing the Effects of Niraparib and Temozolomide Plus Atezolizumab vs. Atezolizumab as Maintenance Therapy in Participants With Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy (TRIO-US L-06) Recruiting NCT03830918 Phase 1, Phase 2 Niraparib;Temozolomide
41 Phase II Clinical Trial of Toripalimab (JS001), a Recombinant Humanized Anti-PD-1 Monoclonal PD1 Antibody, as Monotherapy for Patients With Small Cell Esophageal Carcinoma Who Failed Chemotherapy Recruiting NCT03811379 Phase 2 Toripalimab
42 Phase II Study of Nab-Paclitaxel With Gemcitabine for Relapsed Small Cell Cancer or Those With Progression on First Line Therapy Recruiting NCT02769832 Phase 2 Nab-paclitaxel;Gemcitabine
43 Phase II Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors Recruiting NCT02721732 Phase 2
44 Phase 1/2 Study of Navitoclax Plus Vistusertib in Patients With Relapsed Small Cell Lung Cancer (SCLC) and Other Solid Tumors Recruiting NCT03366103 Phase 1, Phase 2 Vistusertib
45 A Phase I/II Trial of PARP Inhibition, Radiation, and Immunotherapy in Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC) - PRIO Trial Recruiting NCT04728230 Phase 1, Phase 2 Carboplatin;Etoposide;Olaparib
46 A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors Recruiting NCT02498613 Phase 2 Cediranib;Cediranib Maleate;Olaparib
47 A Phase I/II Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor in Small Cell Cancers Recruiting NCT02487095 Phase 1, Phase 2 Topotecan;VX-970 (M6620)
48 Radiation Enhancement of Local and Systemic Anti-Prostate Cancer Immune Responses Recruiting NCT03649841 Phase 2 Antiandrogen Therapy;Abiraterone Acetate;Prednisone
49 A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC) Recruiting NCT03866382 Phase 2 Cabozantinib S-malate
50 Stereotactic Radiosurgery (SRS) as Definitive Management for a Limited Number of Small Cell Lung Cancer (SCLC) Brain Metastasis Recruiting NCT04516070 Phase 2

Search NIH Clinical Center for Lung Oat Cell Carcinoma

Cochrane evidence based reviews: carcinoma, small cell

Genetic Tests for Lung Oat Cell Carcinoma

Anatomical Context for Lung Oat Cell Carcinoma

MalaCards organs/tissues related to Lung Oat Cell Carcinoma:

40
Lung, Prostate, Cervix, Bone, Brain, Thymus, Bone Marrow

Publications for Lung Oat Cell Carcinoma

Articles related to Lung Oat Cell Carcinoma:

(show all 25)
# Title Authors PMID Year
1
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. 6
26619011 2016
2
Prospective enterprise-level molecular genotyping of a cohort of cancer patients. 6
25157968 2014
3
Molecular profiling of small cell lung cancer in a Japanese cohort. 6
24657128 2014
4
Oncogenic point mutations in the human retinoblastoma gene: their application to genetic counseling. 6
2594029 1989
5
Retinochoroidal mass: a presenting feature of metastatic oat cell carcinoma of lung. 61
12510727 2002
6
Orthopaedic clinical note. Patella metastases: a case report. 61
9114685 1997
7
Neurophysins as markers of vasopressin and oxytocin release. A study in carcinoma of the lung. 54
1966564 1990
8
Breast lumps: rare presentation of oat cell carcinoma of lung. 61
2832451 1988
9
[Transplantation model of human lung oat cell carcinoma in nude mice]. 61
2838233 1987
10
Lytic and transforming functions of individual products of the adenovirus E1A gene. 61
2936898 1986
11
Oat cell carcinoma of lung masquerading as prostatic carcinoma. 61
2981444 1985
12
Opsoclonus and oat cell carcinoma of lung: lack of evidence for anti-CNS antibodies. 61
6145928 1984
13
Corticotropin releasing factor: a new tool for the differential diagnosis of Cushing's syndrome. 61
6304135 1983
14
[Association of small peripheral lung cancer and early stomach cancer]. 61
6303280 1983
15
Comparison of survival in patients with non-oat cell carcinoma of lung using various types of treatment modalities. 61
7141935 1982
16
Bone marrow biopsy in solid cancer. 61
6812351 1982
17
Spontaneous disappearance of psoriasis as presenting feature of oat-cell carcinoma of lung. 61
6254604 1980
18
Small cell anaplastic (oat cell) carcinoma of the larynx: report of a case and review of the literature. 61
212654 1978
19
Liver metastases of oat cell carcinoma of lung detected on 99mTc-diphosphonate bone scan. 61
214265 1978
20
Undifferentiated small-cell (oat-cell) carcinoma of lung: prospects for long-term survival. 61
196238 1977
21
Letter: Management of metastatic oat cell carcinoma of lung. 61
4800318 1973
22
Treatment of oat-cell carcinoma of lung. 61
4177195 1968
23
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 14-1966. Oat-cell carcinoma of lung, with extension to local lymph nodes, (associated with inappropriate secretion of antidiuretic hormone). 61
17926383 1966
24
WEEKLY Clinicopathological Exercises: oat-cell carcinoma of lung, left lower, with metastases to regional and abdominal lymph nodes, lungs, pericardium, liver, adrenal glands and vertebrae. 61
13099478 1953
25
Oat-cell carcinoma of lung. 61
21003945 1945

Variations for Lung Oat Cell Carcinoma

ClinVar genetic disease variations for Lung Oat Cell Carcinoma:

6 (show top 50) (show all 106)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 RB1 NM_000321.3(RB1):c.1215+1G>A SNV Pathogenic 126832 rs587776783 GRCh37: 13:48947629-48947629
GRCh38: 13:48373493-48373493
2 overlap with 54 genes t(2;2)(p23;p21)(hg19 chr2:g.42552694::ochr2:g.29446394) Inversion Pathogenic 487484 GRCh37: 2:29446394-42552694
GRCh38:
3 RB1 NM_000321.2(RB1):c.2242G>T (p.Glu748Ter) SNV Pathogenic 13078 rs121913297 GRCh37: 13:49039164-49039164
GRCh38: 13:48465028-48465028
4 RB1 NM_000321.3(RB1):c.1981C>T SNV Pathogenic 13087 rs137853294 GRCh37: 13:49033844-49033844
GRCh38: 13:48459708-48459708
5 RB1 NM_000321.2(RB1):c.2117G>T (p.Cys706Phe) SNV Likely pathogenic 376330 rs121913295 GRCh37: 13:49037877-49037877
GRCh38: 13:48463741-48463741
6 TP53 NM_000546.5(TP53):c.746G>T (p.Arg249Met) SNV Likely pathogenic 376653 rs587782329 GRCh37: 17:7577535-7577535
GRCh38: 17:7674217-7674217
7 TP53 NM_000546.5(TP53):c.518T>G (p.Val173Gly) SNV Likely pathogenic 376016 rs1057519747 GRCh37: 17:7578412-7578412
GRCh38: 17:7675094-7675094
8 TP53 NM_000546.5(TP53):c.373A>C (p.Thr125Pro) SNV Likely pathogenic 376666 rs1057520003 GRCh37: 17:7579314-7579314
GRCh38: 17:7675996-7675996
9 TP53 NM_000546.5(TP53):c.856G>C (p.Glu286Gln) SNV Likely pathogenic 376591 rs786201059 GRCh37: 17:7577082-7577082
GRCh38: 17:7673764-7673764
10 TP53 NM_000546.5(TP53):c.746G>C (p.Arg249Thr) SNV Likely pathogenic 376015 rs587782329 GRCh37: 17:7577535-7577535
GRCh38: 17:7674217-7674217
11 TP53 NM_000546.5(TP53):c.536A>G (p.His179Arg) SNV Likely pathogenic 376606 rs1057519991 GRCh37: 17:7578394-7578394
GRCh38: 17:7675076-7675076
12 TP53 NM_000546.5(TP53):c.658T>A (p.Tyr220Asn) SNV Likely pathogenic 376688 rs530941076 GRCh37: 17:7578191-7578191
GRCh38: 17:7674873-7674873
13 PIK3CA NM_006218.4(PIK3CA):c.1624G>A (p.Glu542Lys) SNV Likely pathogenic 31944 rs121913273 GRCh37: 3:178936082-178936082
GRCh38: 3:179218294-179218294
14 PIK3CA NM_006218.4(PIK3CA):c.1633G>A (p.Glu545Lys) SNV Likely pathogenic 13655 rs104886003 GRCh37: 3:178936091-178936091
GRCh38: 3:179218303-179218303
15 TP53 NM_000546.5(TP53):c.487T>C (p.Tyr163His) SNV Likely pathogenic 376680 rs786203436 GRCh37: 17:7578443-7578443
GRCh38: 17:7675125-7675125
16 TP53 NM_000546.5(TP53):c.700T>A (p.Tyr234Asn) SNV Likely pathogenic 376692 rs864622237 GRCh37: 17:7577581-7577581
GRCh38: 17:7674263-7674263
17 PIK3CA NM_006218.4(PIK3CA):c.1634A>C (p.Glu545Ala) SNV Likely pathogenic 13659 rs121913274 GRCh37: 3:178936092-178936092
GRCh38: 3:179218304-179218304
18 TP53 NM_000546.6(TP53):c.742C>T (p.Arg248Trp) SNV Likely pathogenic 12347 rs121912651 GRCh37: 17:7577539-7577539
GRCh38: 17:7674221-7674221
19 TP53 NM_000546.6(TP53):c.743G>A (p.Arg248Gln) SNV Likely pathogenic 12356 rs11540652 GRCh37: 17:7577538-7577538
GRCh38: 17:7674220-7674220
20 TP53 NM_000546.6(TP53):c.820G>T SNV Likely pathogenic 376674 rs1057520005 GRCh37: 17:7577118-7577118
GRCh38: 17:7673800-7673800
21 TP53 NM_000546.6(TP53):c.818G>A (p.Arg273His) SNV Likely pathogenic 12366 rs28934576 GRCh37: 17:7577120-7577120
GRCh38: 17:7673802-7673802
22 PTEN NM_000314.7(PTEN):c.389G>A (p.Arg130Gln) SNV Likely pathogenic 7829 rs121909229 GRCh37: 10:89692905-89692905
GRCh38: 10:87933148-87933148
23 TP53 NM_000546.5(TP53):c.517G>A (p.Val173Met) SNV Likely pathogenic 233951 rs876660754 GRCh37: 17:7578413-7578413
GRCh38: 17:7675095-7675095
24 TP53 NM_000546.5(TP53):c.701A>C (p.Tyr234Ser) SNV Likely pathogenic 376690 rs587780073 GRCh37: 17:7577580-7577580
GRCh38: 17:7674262-7674262
25 TP53 NM_000546.6(TP53):c.659A>G (p.Tyr220Cys) SNV Likely pathogenic 127819 rs121912666 GRCh37: 17:7578190-7578190
GRCh38: 17:7674872-7674872
26 TP53 NM_000546.5(TP53):c.700T>C (p.Tyr234His) SNV Likely pathogenic 376691 rs864622237 GRCh37: 17:7577581-7577581
GRCh38: 17:7674263-7674263
27 TP53 NM_000546.5(TP53):c.700T>G (p.Tyr234Asp) SNV Likely pathogenic 219759 rs864622237 GRCh37: 17:7577581-7577581
GRCh38: 17:7674263-7674263
28 TP53 NM_000546.5(TP53):c.701A>G (p.Tyr234Cys) SNV Likely pathogenic 127820 rs587780073 GRCh37: 17:7577580-7577580
GRCh38: 17:7674262-7674262
29 TP53 NM_000546.5(TP53):c.487T>G (p.Tyr163Asp) SNV Likely pathogenic 187052 rs786203436 GRCh37: 17:7578443-7578443
GRCh38: 17:7675125-7675125
30 TP53 NM_000546.5(TP53):c.839G>C (p.Arg280Thr) SNV Likely pathogenic 12368 rs121912660 GRCh37: 17:7577099-7577099
GRCh38: 17:7673781-7673781
31 TP53 NM_000546.5(TP53):c.643A>G (p.Ser215Gly) SNV Likely pathogenic 265337 rs886039484 GRCh37: 17:7578206-7578206
GRCh38: 17:7674888-7674888
32 TP53 NM_000546.5(TP53):c.838A>G (p.Arg280Gly) SNV Likely pathogenic 376658 rs753660142 GRCh37: 17:7577100-7577100
GRCh38: 17:7673782-7673782
33 PIK3CA NM_006218.4(PIK3CA):c.1624G>C (p.Glu542Gln) SNV Likely pathogenic 376244 rs121913273 GRCh37: 3:178936082-178936082
GRCh38: 3:179218294-179218294
34 TP53 NM_000546.5(TP53):c.857A>G (p.Glu286Gly) SNV Likely pathogenic 376590 rs1057519985 GRCh37: 17:7577081-7577081
GRCh38: 17:7673763-7673763
35 TP53 NM_000546.5(TP53):c.587G>C (p.Arg196Pro) SNV Likely pathogenic 231165 rs483352697 GRCh37: 17:7578262-7578262
GRCh38: 17:7674944-7674944
36 TP53 NM_000546.5(TP53):c.535C>G (p.His179Asp) SNV Likely pathogenic 376610 rs587780070 GRCh37: 17:7578395-7578395
GRCh38: 17:7675077-7675077
37 TP53 NM_000546.5(TP53):c.644G>T (p.Ser215Ile) SNV Likely pathogenic 376660 rs587782177 GRCh37: 17:7578205-7578205
GRCh38: 17:7674887-7674887
38 TP53 NM_000546.5(TP53):c.518T>A (p.Val173Glu) SNV Likely pathogenic 376669 rs1057519747 GRCh37: 17:7578412-7578412
GRCh38: 17:7675094-7675094
39 TP53 NM_000546.5(TP53):c.578A>T (p.His193Leu) SNV Likely pathogenic 185822 rs786201838 GRCh37: 17:7578271-7578271
GRCh38: 17:7674953-7674953
40 PIK3CA NM_006218.4(PIK3CA):c.1625A>C (p.Glu542Ala) SNV Likely pathogenic 376473 rs1057519927 GRCh37: 3:178936083-178936083
GRCh38: 3:179218295-179218295
41 AKT1 NM_005163.2(AKT1):c.49G>A (p.Glu17Lys) SNV Likely pathogenic 13983 rs121434592 GRCh37: 14:105246551-105246551
GRCh38: 14:104780214-104780214
42 TP53 NM_000546.5(TP53):c.535C>A (p.His179Asn) SNV Likely pathogenic 376609 rs587780070 GRCh37: 17:7578395-7578395
GRCh38: 17:7675077-7675077
43 TP53 NM_000546.5(TP53):c.731G>A (p.Gly244Asp) SNV Likely pathogenic 372785 rs985033810 GRCh37: 17:7577550-7577550
GRCh38: 17:7674232-7674232
44 TP53 NM_000546.5(TP53):c.578A>C (p.His193Pro) SNV Likely pathogenic 376612 rs786201838 GRCh37: 17:7578271-7578271
GRCh38: 17:7674953-7674953
45 TP53 NM_000546.5(TP53):c.535C>T (p.His179Tyr) SNV Likely pathogenic 127815 rs587780070 GRCh37: 17:7578395-7578395
GRCh38: 17:7675077-7675077
46 PTEN NM_000314.8(PTEN):c.389G>T SNV Likely pathogenic 376509 rs121909229 GRCh37: 10:89692905-89692905
GRCh38: 10:87933148-87933148
47 TP53 NM_000546.5(TP53):c.374C>G (p.Thr125Arg) SNV Likely pathogenic 376667 rs786201057 GRCh37: 17:7579313-7579313
GRCh38: 17:7675995-7675995
48 TP53 NM_000546.5(TP53):c.488A>G (p.Tyr163Cys) SNV Likely pathogenic 127814 rs148924904 GRCh37: 17:7578442-7578442
GRCh38: 17:7675124-7675124
49 TP53 NM_000546.5(TP53):c.730G>A (p.Gly244Ser) SNV Likely pathogenic 376600 rs1057519989 GRCh37: 17:7577551-7577551
GRCh38: 17:7674233-7674233
50 TP53 NM_000546.5(TP53):c.821T>A (p.Val274Asp) SNV Likely pathogenic 376675 rs1057520006 GRCh37: 17:7577117-7577117
GRCh38: 17:7673799-7673799

Cosmic variations for Lung Oat Cell Carcinoma:

9 (show top 50) (show all 1540)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM102042323 ZFHX3 lung,NS,carcinoma,undifferentiated carcinoma c.-23-8009A>G p.? 16:72958974-72958974 6
2 COSM87291734 ZFHX3 lung,NS,carcinoma,undifferentiated carcinoma c.1172A>G p.Q391R 16:72958974-72958974 6
3 COSM102040476 ZFHX3 lung,NS,carcinoma,undifferentiated carcinoma c.-23-8037G>T p.? 16:72959002-72959002 6
4 COSM149314749 ZFHX3 lung,NS,carcinoma,undifferentiated carcinoma c.1144G>T p.G382C 16:72959002-72959002 6
5 COSM87290218 ZFHX3 lung,NS,carcinoma,undifferentiated carcinoma c.1144G>T p.G382C 16:72959002-72959002 6
6 COSM149318860 ZFHX3 lung,NS,carcinoma,undifferentiated carcinoma c.1172A>G p.Q391R 16:72958974-72958974 6
7 COSM126973051 YAP1 lung,NS,carcinoma,undifferentiated carcinoma c.770C>T p.P257L 11:102229729-102229729 6
8 COSM145028029 YAP1 lung,NS,carcinoma,undifferentiated carcinoma c.1154C>T p.P385L 11:102229729-102229729 6
9 COSM128452039 YAP1 lung,NS,carcinoma,undifferentiated carcinoma c.1142C>T p.P381L 11:102229729-102229729 6
10 COSM85237448 YAP1 lung,NS,carcinoma,undifferentiated carcinoma c.1304C>T p.P435L 11:102229729-102229729 6
11 COSM143041512 YAP1 lung,NS,carcinoma,undifferentiated carcinoma c.1316C>T p.P439L 11:102229729-102229729 6
12 COSM127997731 YAP1 lung,NS,carcinoma,undifferentiated carcinoma c.1256C>T p.P419L 11:102229729-102229729 6
13 COSM133274224 YAP1 lung,NS,carcinoma,undifferentiated carcinoma c.1268C>T p.P423L 11:102229729-102229729 6
14 COSM90948266 YAP1 lung,NS,carcinoma,undifferentiated carcinoma c.1202C>T p.P401L 11:102229729-102229729 6
15 COSM108017622 XRCC6 lung,NS,carcinoma,undifferentiated carcinoma c.1009A>C p.I337L 22:41653558-41653558 6
16 COSM95166535 XRCC6 lung,NS,carcinoma,undifferentiated carcinoma c.1159A>C p.I387L 22:41653558-41653558 6
17 COSM97230831 XRCC6 lung,NS,carcinoma,undifferentiated carcinoma c.1159A>C p.I387L 22:41653558-41653558 6
18 COSM105839764 XRCC6 lung,NS,carcinoma,undifferentiated carcinoma c.1009A>C p.I337L 22:41653558-41653558 6
19 COSM106337415 XRCC6 lung,NS,carcinoma,undifferentiated carcinoma c.1159A>C p.I387L 22:41653558-41653558 6
20 COSM103711109 XRCC6 lung,NS,carcinoma,undifferentiated carcinoma c.1036A>C p.I346L 22:41653558-41653558 6
21 COSM85312404 XRCC1 lung,NS,carcinoma,undifferentiated carcinoma c.1207A>G p.M403V 19:43546970-43546970 6
22 COSM134125623 XRCC1 lung,NS,carcinoma,undifferentiated carcinoma c.1114A>G p.M372V 19:43546970-43546970 6
23 COSM100781761 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.724A>T p.K242* 11:32392044-32392044 6
24 COSM111539040 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.1309A>T p.K437* 11:32392044-32392044 6
25 COSM149728755 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.437G>A p.W146* 11:32434909-32434909 6
26 COSM130518653 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.673A>T p.K225* 11:32392044-32392044 6
27 COSM113475703 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.437G>A p.W146* 11:32434909-32434909 6
28 COSM111529696 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.437G>A p.W146* 11:32434909-32434909 6
29 COSM113484991 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.1360A>T p.K454* 11:32392044-32392044 6
30 COSM147414475 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.437G>A p.W146* 11:32434909-32434909 6
31 COSM149739953 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.1360A>T p.K454* 11:32392044-32392044 6
32 COSM148580942 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.437G>A p.W146* 11:32434909-32434909 6
33 COSM148593279 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.1360A>T p.K454* 11:32392044-32392044 6
34 COSM91372655 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.437G>A p.W146* 11:32434909-32434909 6
35 COSM91383011 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.1360A>T p.K454* 11:32392044-32392044 6
36 COSM147426277 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.1309A>T p.K437* 11:32392044-32392044 6
37 COSM124478343 WNT8A lung,NS,carcinoma,undifferentiated carcinoma c.422G>C p.G141A 5:138088927-138088927 6
38 COSM104050903 WNT8A lung,NS,carcinoma,undifferentiated carcinoma c.368G>C p.G123A 5:138088927-138088927 6
39 COSM105123686 WNT10B lung,NS,carcinoma,undifferentiated carcinoma c.*288A>C p.? 12:48966259-48966259 6
40 COSM87652733 WNT10B lung,NS,carcinoma,undifferentiated carcinoma c.1006A>C p.K336Q 12:48966259-48966259 6
41 COSM102763785 WNT10B lung,NS,carcinoma,undifferentiated carcinoma c.*288A>C p.? 12:48966259-48966259 6
42 COSM99767946 USP5 lung,NS,carcinoma,undifferentiated carcinoma c.755C>T p.T252I 12:6856877-6856877 6
43 COSM84601598 USP5 lung,NS,carcinoma,undifferentiated carcinoma c.755C>T p.T252I 12:6856877-6856877 6
44 COSM121848752 USP38 lung,NS,carcinoma,undifferentiated carcinoma c.994G>C p.A332P 4:143197868-143197868 6
45 COSM88410243 USP38 lung,NS,carcinoma,undifferentiated carcinoma c.994G>C p.A332P 4:143197868-143197868 6
46 COSM87541563 USP32 lung,NS,carcinoma,undifferentiated carcinoma c.192T>A p.I64= 17:60301699-60301699 6
47 COSM99795256 USP32 lung,NS,carcinoma,undifferentiated carcinoma c.192T>A p.I64= 17:60301699-60301699 6
48 COSM143996084 UHRF1 lung,NS,carcinoma,undifferentiated carcinoma c.1620C>G p.F540L 19:4947122-4947122 6
49 COSM143964403 UHRF1 lung,NS,carcinoma,undifferentiated carcinoma c.1428C>G p.F476L 19:4947122-4947122 6
50 COSM145430147 UHRF1 lung,NS,carcinoma,undifferentiated carcinoma c.1467C>G p.F489L 19:4947122-4947122 6

Expression for Lung Oat Cell Carcinoma

Search GEO for disease gene expression data for Lung Oat Cell Carcinoma.

Pathways for Lung Oat Cell Carcinoma

Pathways related to Lung Oat Cell Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 67)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.96 TP53 RB1 PTEN PIK3CA AKT1
2
Show member pathways
12.87 TP53 RB1 PTEN PIK3CA AKT1
3
Show member pathways
12.81 TP53 RB1 PIK3CA B2M AKT1
4
Show member pathways
12.8 RB1 PTEN PIK3CA AKT1
5
Show member pathways
12.74 TP53 RB1 PTEN PIK3CA AKT1
6 12.71 TP53 PIK3CA B2M AKT1
7 12.7 TP53 RB1 PTEN PIK3CA AKT1
8
Show member pathways
12.68 TP53 RB1 PIK3CA B2M AKT1
9
Show member pathways
12.64 TP53 PTEN PIK3CA AKT1
10
Show member pathways
12.62 TP53 PTEN PIK3CA AKT1
11
Show member pathways
12.61 TP53 RB1 PTEN PIK3CA AKT1
12
Show member pathways
12.52 TP53 PTEN PIK3CA AKT1
13
Show member pathways
12.52 TP53 RB1 PTEN PIK3CA AKT1
14
Show member pathways
12.41 TP53 PTEN PIK3CA AKT1
15
Show member pathways
12.4 TP53 PTEN PIK3CA AKT1
16
Show member pathways
12.29 TP53 PTEN PIK3CA AKT1
17 12.22 TP53 PIK3CA AKT1
18 12.22 TP53 RB1 PIK3CA
19
Show member pathways
12.21 TP53 PTEN PIK3CA AKT1
20
Show member pathways
12.13 TP53 RB1 PTEN AKT1
21
Show member pathways
12.1 TP53 PIK3CA AKT1
22
Show member pathways
12.1 PTEN PIK3CA AKT1
23
Show member pathways
12.07 TP53 PIK3CA AKT1
24
Show member pathways
12.06 PTEN PIK3CA AKT1
25
Show member pathways
12.04 TP53 RB1 PTEN PIK3CA AKT1
26 12.02 TP53 PIK3CA AKT1
27
Show member pathways
12.02 PTEN PIK3CA AKT1
28 12.02 TP53 RB1 PTEN AKT1
29 12.01 PTEN PIK3CA AKT1
30 11.99 TP53 RB1 PTEN
31
Show member pathways
11.96 TP53 PIK3CA AKT1
32 11.94 TP53 PIK3CA AKT1
33 11.91 TP53 POMC AKT1
34
Show member pathways
11.89 PTEN PIK3CA AKT1
35 11.89 PIK3CA ENO2 AKT1
36
Show member pathways
11.88 PTEN B2M AKT1
37 11.87 TP53 RB1 PTEN
38 11.87 TP53 PTEN PIK3CA AKT1
39 11.84 TP53 PTEN PIK3CA AKT1
40 11.8 PTEN PIK3CA AKT1
41 11.79 RB1 PTEN AKT1
42 11.78 TP53 RB1 PTEN AKT1
43 11.76 TP53 PTEN AKT1
44 11.75 TP53 RB1 PTEN PIK3CA AKT1
45 11.74 TP53 POMC AKT1
46 11.67 TP53 PIK3CA AKT1
47 11.63 RB1 PIK3CA AKT1
48
Show member pathways
11.61 TP53 PIK3CA AKT1
49
Show member pathways
11.55 RB1 PIK3CA AKT1
50 11.55 TP53 PTEN PIK3CA AKT1

GO Terms for Lung Oat Cell Carcinoma

Cellular components related to Lung Oat Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 PML body GO:0016605 9.13 TP53 RB1 PTEN
2 secretory granule GO:0030141 8.8 POMC CHGA AVP

Biological processes related to Lung Oat Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.88 TP53 PTEN AVP AKT1
2 positive regulation of gene expression GO:0010628 9.87 TP53 PTEN AVP AKT1
3 regulation of cell cycle GO:0051726 9.72 TP53 RB1 PTEN
4 apoptotic process GO:0006915 9.72 TP53 RB1 PTEN AVP AKT1
5 cellular response to hypoxia GO:0071456 9.69 TP53 PTEN AKT1
6 cytokine-mediated signaling pathway GO:0019221 9.67 TP53 POMC PIK3CA AKT1
7 negative regulation of proteolysis GO:0045861 9.59 TP53 AKT1
8 negative regulation of protein serine/threonine kinase activity GO:0071901 9.58 RB1 AKT1
9 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.58 PIK3CA AVP AKT1
10 negative regulation of release of cytochrome c from mitochondria GO:0090201 9.56 AVP AKT1
11 striated muscle cell differentiation GO:0051146 9.54 RB1 AKT1
12 positive regulation of cardiac muscle cell apoptotic process GO:0010666 9.52 TP53 PTEN
13 negative regulation of macroautophagy GO:0016242 9.49 PIK3CA AKT1
14 anoikis GO:0043276 9.48 PIK3CA AKT1
15 maternal behavior GO:0042711 9.46 PTEN AVP
16 negative regulation of cell size GO:0045792 9.43 PTEN AKT1
17 negative regulation of epithelial cell proliferation GO:0050680 9.43 RB1 PTEN B2M
18 cellular response to decreased oxygen levels GO:0036294 9.16 PTEN AKT1
19 protein kinase B signaling GO:0043491 9.13 PTEN PIK3CA AKT1
20 phosphatidylinositol 3-kinase signaling GO:0014065 8.8 PTEN PIK3CA AKT1

Molecular functions related to Lung Oat Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 enzyme binding GO:0019899 8.92 TP53 RB1 PTEN AKT1

Sources for Lung Oat Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....